Emcure Pharmaceuticals has reduced price of its weight management drug Poviztra (semaglutide injection) across India. The reduced price would be starting at Rs 3,999 per month (MRP inclusive of taxes) (4 weekly doses). The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing.

As the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s semaglutide injection for obesity, the company aims to expand access and enable more patients to benefit from this proven therapy at the revised price. The price revision, effective April 03, 2026, will bring the innovator molecule, backed by robust clinical and real-world evidence, within the reach of a significantly larger patient base across the country - at a time when obesity and weight-related health conditions are emerging as one of India’s most pressing public health challenges.

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.